GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » EV-to-Revenue

Enzychem Lifesciences (XKRX:183490) EV-to-Revenue : 0.46 (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Enzychem Lifesciences's enterprise value is ₩37,650 Mil. Enzychem Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩82,650 Mil. Therefore, Enzychem Lifesciences's EV-to-Revenue for today is 0.46.

The historical rank and industry rank for Enzychem Lifesciences's EV-to-Revenue or its related term are showing as below:

XKRX:183490' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.68   Med: 17.56   Max: 71.98
Current: 0.46

During the past 10 years, the highest EV-to-Revenue of Enzychem Lifesciences was 71.98. The lowest was -3.68. And the median was 17.56.

XKRX:183490's EV-to-Revenue is ranked better than
92.77% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs XKRX:183490: 0.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Enzychem Lifesciences's stock price is ₩1879.00. Enzychem Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩977.57. Therefore, Enzychem Lifesciences's PS Ratio for today is 1.92.


Enzychem Lifesciences EV-to-Revenue Historical Data

The historical data trend for Enzychem Lifesciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences EV-to-Revenue Chart

Enzychem Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.24 31.83 18.06 -0.57 0.32

Enzychem Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.30 -0.17 0.32 0.47

Competitive Comparison of Enzychem Lifesciences's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzychem Lifesciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's EV-to-Revenue falls into.



Enzychem Lifesciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Enzychem Lifesciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=37649.875/82649.793
=0.46

Enzychem Lifesciences's current Enterprise Value is ₩37,650 Mil.
Enzychem Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩82,650 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzychem Lifesciences  (XKRX:183490) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Enzychem Lifesciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1879.00/977.572
=1.92

Enzychem Lifesciences's share price for today is ₩1879.00.
Enzychem Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩977.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzychem Lifesciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences (XKRX:183490) Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences (XKRX:183490) Headlines

No Headlines